Knight Therapeutics Inc. (GUD : TSX)
Common Stock
$9.26
CAD
-0.08 (-0.86%)
Last updated: 2026-08-05
Get GUD alerts:
GUD
Knight Therapeutics Inc.
WealthAwesomePerformance
1 Day
-0.86%
1 Week
-6.18%
1 Month
-7.31%
YTD
+56.68%
Key Statistics
Market Cap
$917.00M
52W High
$10.17
52W Low
$5.66
P/E Ratio
155.67
50 Day MA
$9.34
200 Day MA
$7.21
Beta
0.05
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 8/5/2026 | $9.34 | $9.36 | $9.22 | $9.26 | $9.26 | 183,703 |
| 8/4/2026 | $9.84 | $9.85 | $9.31 | $9.34 | $9.34 | 107,223 |
| 7/31/2026 | $9.59 | $9.93 | $9.59 | $9.84 | $9.84 | 60,300 |
| 7/30/2026 | $9.80 | $9.95 | $9.72 | $9.77 | $9.77 | 59,581 |
| 7/29/2026 | $9.84 | $10.00 | $9.77 | $9.87 | $9.87 | 50,036 |
| 7/28/2026 | $9.83 | $9.88 | $9.78 | $9.84 | $9.84 | 58,681 |
| 7/27/2026 | $9.72 | $9.87 | $9.72 | $9.82 | $9.82 | 51,974 |
| 7/24/2026 | $9.68 | $9.80 | $9.68 | $9.73 | $9.73 | 32,378 |
| 7/23/2026 | $9.75 | $9.76 | $9.67 | $9.69 | $9.69 | 66,903 |
| 7/22/2026 | $9.98 | $10.05 | $9.65 | $9.68 | $9.68 | 131,460 |
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 6.1% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
+6.1% Upside
Current Price
C$9.26
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.8%
Annualized
90-Day Vol
30.1%
Annualized
Trend (90d)
+26.7%
Annualized drift
90d Mean
C$10.19
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.56 | C$8.80 – C$10.38 |
| 60 trading days | C$9.87 | C$8.78 – C$11.08 |
| 90 trading days | C$10.19 | C$8.83 – C$11.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Financials
- Revenue (TTM)
- $510.45M
- EBITDA
- $70.12M
- Profit Margin
- 1.10%
- ROE (TTM)
- 0.71%
- EPS (Diluted)
- 0.06
- Book Value
- 8.01
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GUD
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
GUD.TO news timeline
9 articles covering GUD.TO, most recent first
Latest